Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Slutsky is a top 100 analyst with an average return of 43.2% and a 51.21% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Abivax SA Sponsored ADR, and Palvella Therapeutics.
Currently, the analyst consensus on Spyre Therapeutics is a Strong Buy with an average price target of $95.86.
Based on Spyre Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $69.01 million. In comparison, last year the company had a GAAP net loss of $44.77 million
